Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to post $5.53 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ADMA Biologics’ earnings. The highest sales estimate is $6.00 million and the lowest is $5.06 million. ADMA Biologics reported sales of $3.40 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 62.6%. The company is expected to report its next earnings results on Friday, August 10th.
According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $22.71 million for the current fiscal year, with estimates ranging from $22.41 million to $23.00 million. For the next financial year, analysts forecast that the firm will post sales of $80.71 million per share, with estimates ranging from $50.33 million to $111.10 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow ADMA Biologics.
Several research firms have recently issued reports on ADMA. LADENBURG THALM/SH SH reduced their target price on shares of ADMA Biologics to $7.50 and set a “buy” rating for the company in a research note on Wednesday. ValuEngine upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Finally, Maxim Group set a $10.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Tuesday, April 24th.
In related news, CEO Adam S. Grossman purchased 52,301 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the transaction, the chief executive officer now owns 32,527 shares in the company, valued at $155,479.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman purchased 20,921 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average price of $4.78 per share, with a total value of $100,002.38. Following the transaction, the director now owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. In the last quarter, insiders bought 78,222 shares of company stock valued at $373,901. Company insiders own 16.90% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ADMA. Geode Capital Management LLC grew its position in ADMA Biologics by 420.3% during the fourth quarter. Geode Capital Management LLC now owns 112,000 shares of the biotechnology company’s stock valued at $359,000 after buying an additional 90,474 shares during the period. Broadfin Capital LLC bought a new position in ADMA Biologics during the fourth quarter valued at about $3,538,000. Stonepine Capital Management LLC bought a new position in ADMA Biologics during the fourth quarter valued at about $217,000. Consonance Capital Management LP grew its position in ADMA Biologics by 164.3% during the fourth quarter. Consonance Capital Management LP now owns 3,367,635 shares of the biotechnology company’s stock valued at $10,810,000 after buying an additional 2,093,702 shares during the period. Finally, Morgens Waterfall Vintiadis & Co. Inc. bought a new position in ADMA Biologics during the fourth quarter valued at about $1,605,000. Institutional investors own 37.42% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.